- Report
- March 2025
- 110 Pages
Global
From €2627EUR$2,950USD£2,291GBP
- Report
- March 2025
- 82 Pages
Middle East, Africa
From €2627EUR$2,950USD£2,291GBP
- Report
- March 2025
- 82 Pages
From €2627EUR$2,950USD£2,291GBP
- Report
- March 2025
- 96 Pages
Asia Pacific
From €3072EUR$3,450USD£2,679GBP
- Report
- March 2025
- 99 Pages
Europe
From €3072EUR$3,450USD£2,679GBP
- Report
- March 2025
- 88 Pages
North America
From €2627EUR$2,950USD£2,291GBP
- Report
- December 2024
- 150 Pages
Global
From €3339EUR$3,750USD£2,912GBP
- Report
- July 2024
- 26 Pages
Global
From €1737EUR$1,950USD£1,514GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Clinical Trials
- April 2024
- 481 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- March 2024
- 44 Pages
Global
From €8901EUR$9,995USD£7,762GBP
- Report
- October 2023
- 689 Pages
Global
From €8901EUR$9,995USD£7,762GBP
- Report
- August 2023
- 106 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- July 2023
- 808 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- July 2023
- 457 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- June 2023
- 33 Pages
Global
From €1737EUR$1,950USD£1,514GBP
- Report
- July 2024
- 154 Pages
Global
From €3217EUR$3,613USD£2,805GBP
€3785EUR$4,250USD£3,300GBP
- Report
- July 2024
- 158 Pages
Global
From €3217EUR$3,613USD£2,805GBP
€3785EUR$4,250USD£3,300GBP
- Report
- July 2024
- 153 Pages
Global
From €3217EUR$3,613USD£2,805GBP
€3785EUR$4,250USD£3,300GBP
- Report
- August 2024
- 82 Pages
Global
From €3500EUR$4,210USD£3,159GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more